Award Year / Program / Phase:2010 / SBIR / Phase I
Agency:HHS
Principal Investigator:Eric Ervin
Award Amount:$168,098.00
Abstract:
DESCRIPTION (provided by applicant): The overall aim of this Phase I program is to develop a new, robust nanopore platform for the differentiation of pharmacologically relevant enantiomers in clinical samples. Enantiomer screening is an important aspect of
drug manufacturing and pharmacokinetic… More
DESCRIPTION (provided by applicant): This Phase II SBIR program aims to further develop Electronic Bio Sciences' (EBS) Nanopatch system for ion channel measurements. The proposed system will allow high sensitivity measurements previously only attainable with the patch clamp method to be… More
Award Year / Program / Phase:2011 / SBIR / Phase I
Agency:DOD
Principal Investigator:Eric Ervin, Vice President R&D - EBS Utah – (801) 582-0146
Award Amount:$99,969.00
Abstract:
This Small Business Innovation Research Phase I project will develop a non-animal based in-vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics; the dual nanopore assay (DNPA). New technologies are currently needed in order to facilitate the development and approval… More
Award Year / Program / Phase:2012 / SBIR / Phase II
Agency:DOD
Principal Investigator:Eric Ervin, Vice President of R&D – (801) 582-0146
Award Amount:$1,149,937.00
Abstract:
This Small Business Innovation Research project will develop a non-animal based in vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics. New technologies are currently needed in order to facilitate the development and approval of BoNT vaccines and therapies and… More
DESCRIPTION (provided by applicant): Unknown or poorly understood differences in the potency of therapeutics containing the botulinum neurotoxin Type A (BoNT/A) could result in over or under dosing of patients. The potency of BoNT/A therapeutics is currently assessed using a mouse intraperitoneal… More